INOVARION

About the company

Inovarion is a Life Sciences company based in Paris offering preclinical and fundamental research services.

Since 2013, Inovarion provides support to the pharmaceutical, biotechnology industries and academics in the form of research services outsourced on a contract basis. They help biotech companies to reach clinical trials faster outsourcing their R&D to Inovarion in France.

They have been working as an extension of their partners’ teams for Sanofi, L’Oréal, Inserm (French NIH), Gustave Roussy, and many more.

About the solution

Inovarion has developed a strong expertise in bioinformatics, oncology, immunology and molecular biology.
They are well established in the research landscape in France and published +140 scientific papers in the highest ranked reviews (Nature, Science, The Lancet, Cell…).

Here are their main advantages:
⁃ Scientific French excellence
⁃ Cost effectiveness thanks to French tax credits : 25%-40% less vs US project cost
⁃ Talent loyalty & stability: less than 5% staff turnover per year in our team

Their goal is to build up close and long-term cooperation with pharmaceutical and biotechnologiy companies worldwide, to offer them in France, very attractive conditions, both financial and time-saving, for conducting top-notch fundamental and preclinical research and beyond that, to achieve together scientifical victories in medicine.

Website

Key information

– Therapeutic areas: Immuno-oncology, Neuroscience, Dermatology, Oncology, Immunology

– Based in: Paris (FRANCE)

– Employees: 51-200

– Created in: 2013

BRAINTALE

About the company

BrainTale is an innovative medtech company deciphering white matter to enable faster drug development and better brain care with clinically validated prognostic solutions. With non-invasive, sensitive and reliable measurements of white matter microstructure alterations, BrainTale offers a digital biomarkers platform to support clinical development programs and decision-making in clinical routine.

BrainTale enables the identification of patients at risk, early diagnosis and monitoring of disease progression and the effectiveness of treatments in neurology, in particular for demyelinating diseases such as Multiple Sclerosis and neurodegenerative diseases such as Alzheimer’s Diseases. Based on more than 15 years of research and development, BrainTale’s products are developed to meet the medical needs and expectations of pharma companies and healthcare professionals for the benefit of patients. 

About the solution

BrainTale’s solutions enable access to diffusion MRI markers for drug development and patient care, through a unique technology that enables calibration and standardization of MRI diffusion parameters in a multidevice and multicenter setting. Thus, BrainTale offers quantification of white matter tissue, especially fiber density, axonal degeneration and myelin content, with unlimited potential to support clinical development programs through accurate patient selection and stratification at inclusion, and evaluation of treatment efficacy with highly sensitive and robust biomarkers.

Website

Key information

– Therapeutic areas: Neuroscience, Neurology, Alzheimer’s Disease, Multiple Sclerosis, Traumatic Brain Injury, Rare demyelinating diseases

– Based in: Paris & Strasbourg (FRANCE)

– Employees: 11 – 50

– Created in: 2018